Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in Rural KwaZulu-Natal, South Africa

AIDS Research and Human Retroviruses

Volumn 32, Issue 8, 2016, Pages 763-769

  Manasa, Justen ^a,b   Danaviah, Siva ^a   Lessells, Richard ^a,c   Elshareef, Muna ^a   Tanser, Frank ^a   Wilkinson, Eduan ^a   Pillay, Sureshnee ^a   Mthiyane, Hloniphile ^a   Mwambi, Henry ^a   Pillay, Deenan ^a   De Oliveira, Tulio ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; RNA DIRECTED DNA POLYMERASE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRIED BLOOD SPOT TESTING; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RETROSPECTIVE STUDY; VIROLOGY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; PUBLIC HEALTH SURVEILLANCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA; VIRAL LOAD;

EID: 84980011718     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0225     Document Type: Article

References (37)

1. Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966-971
2. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505
3. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13(Suppl 2): 1-85
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed [April 10, 2016] [Page C-15, Table 5
5. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13: 77-108
6. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks FC. Recommendation for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl 2): 12
7. Jordan MR, Bennett DE, Wainberg MA, et al. Update on World Health Organization HIV drug resistance prevention and assessment strategy 2004-2011. Clin Infect Dis 2012; 54(Suppl 4): S245-S249
8. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2): 15-23
9. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-260
10. Hunt GM, Ledwaba J, Basson AE, et al. Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009. Clin Infect Dis 2012; 54(Suppl 4): S334-S338
11. Parikh UM, Kiepiela P, Ganesh S, et al. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). PLoS One 2013; 8: e59787
12. Parboosing R, Naidoo A, Gordon M, Taylor M, Vella V. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 2011; 83: 1508-1513
13. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira For The Southern Africa T, Resistance Network Saturn T. Primary drug resistance in South Africa: Data from 10 years of surveys. AIDS Res Hum Retroviruses 2012; 28: 558-565
14. Lapadula G, Costarelli S, Quiros-Roldan E, et al. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis 2008; 46: 1127-1129
15. Van Zyl GU, Liu TF, Claassen M, et al. Trends in genotypic HIV-1 antiretroviral resistance between 2006 and 2012 in South African patients receiving first-and second-line antiretroviral treatment regimens. PLoS One 2013; 8: e67188
16. Coriat B. The Political Economy of HIV/AIDS in Developing Countries. TRIPS, Public Health Systems and Free Access. Edward Elgar, Chaltenham, UK. 2008
17. Kearse M, Moir R, Wilson A, et al. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 2012; 28: 1647-1649
18. Alcantara LC, Cassol S, Libin P, et al. A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences. Nucleic Acids Res 2009; 37(Web Server issue): W634-W642
19. Gifford RJ, Liu TF, Rhee SY, et al. The calibrated population resistance tool: Standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics 2009; 25: 1197-1198
20. Pineda-Pena AC, Faria NR, Imbrechts S, et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. Infect Genet Evol 2013; 19: 337-348
21. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: Basic principles and potential controversies. Antivir Ther 2008; 13 (Suppl 2): 59-68
22. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drugresistance 2009 update. PLoS One 2009; 4: e4724
23. Barnighausen T, Wallrauch C, Welte A, et al. HIV incidence in rural South Africa: Comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One 2008; 3: e3640
24. Houlihan CF, Bland RM, Mutevedzi PC, et al. Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 2011; 40: 318-326
25. Barnighausen T, Tanser F, Newell ML. Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses 2009; 25: 405-409
26. Manasa J, Lessells R, Skingsley A, et al. High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa. PLoS One 2013; 8: e72152
27. Hamers RL, Siwale M, Wallis CL, et al. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 55: 95-101
28. Ndembi N, Hamers RL, Sigaloff KC, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS 2011; 25: 905-910
29. Sigaloff KC, Mandaliya K, Hamers RL, et al. High prevalence of transmitted antiretroviral drug resistance among newly HIV type 1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses 2012; 28: 1033-1037
30. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. Aids 2004; 18: 1683-1689
31. Castro H, Pillay D, Cane P, et al. Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis 2013; 208: 1459-1463
32. Clumeck N, Hill A, Moecklinghoff C. Effects of switching to protease inhibitor monotherapy on nucleoside analoguerelated adverse events. AIDS Rev 2014; 16: 236-245
33. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS 2012; 26: 1679-1684
34. Coutsinos D, Invernizzi CF, Moisi D, et al. A templatedependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One 2011; 6: e20208
35. Towner W, Kerrigan H, LaRiviere M, et al. Efficacy of a once-daily regimen of nevirapine(NVP), lamivudine (3TC) and tenofovir (TDF) in treatment-naive HIV-infected patients: A pilot study. 7th International Congress on Drug Therapy in HIV Infection, 14-18 November 2004, Glasgow
36. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510-5518
37. Clumeck N. The challenge: Streamlining HIV treatment and care while improving outcomes. J Int AIDS Soc 2014; 17(4 Suppl 3): 19493